Trial Profile
Phase IIB Randomized, Placebo-Controlled Trial of ACTOplus Met® XR in Subjects With Stage I-IV Squamous Cell Carcinoma of the Oral Cavity or Oropharynx Prior to Definitive Treatment
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 10 Mar 2023
Price :
$35
*
At a glance
- Drugs Metformin/pioglitazone (Primary)
- Indications Oropharyngeal cancer; Squamous cell cancer
- Focus Therapeutic Use
- 17 Sep 2019 Status changed from active, no longer recruiting to discontinued.
- 09 Aug 2019 Status changed from recruiting to active, no longer recruiting.
- 03 Jun 2019 Planned End Date changed from 30 Aug 2019 to 27 Aug 2019.